Year Founded
2022
Ownership
Public
Employees
~1
Stage
Preclinical
Modalities
Bispecific antibody

Tundra Targeted Therapeutics General Information

Developing novel bispecific antibodies that bring patient's T cells into contact with specific antigens on tumor cells. Initial focus on CD30 positive pediatric cancers. Starting human safety and efficacy trials.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Milwaukee, Wisconsin
United States

Drug Pipeline

Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Tundra Targeted Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Tundra Targeted Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Tundra Targeted Therapeutics's complete valuation and funding history, request access »

Tundra Targeted Therapeutics Investors

BrightStar Wisconsin Foundation
Investor Type: Venture Capital
Holding: Minority
Investment date August-2022[1]
Investor Type: Venture Capital
Holding: Minority